COX-1 sparing and COX-2 inhibitory drugs: the renal and hepatic safety and tolerability profiles of celecoxib

Am J Ther. 2000 May;7(3):151-2.

Author

A Whelton¹

Affiliation

¹ The Universal Clinical Research Center, Inc., and the Johns Hopkins University School of Medicine, Maryland, USA.

PMID: 11317163

No abstract available

Publication types

Comment

MeSH terms

Celecoxib
Cyclooxygenase 1
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors / adverse effects*
Cyclooxygenase Inhibitors / pharmacokinetics*
Humans
Isoenzymes / drug effects
Isoenzymes / metabolism
Kidney / drug effects*
Kidney / physiology
Liver / drug effects*
Liver / physiology
Membrane Proteins
Prostaglandin-Endoperoxide Synthases / drug effects
Prostaglandin-Endoperoxide Synthases / metabolism
Pyrazoles
Sulfonamides / adverse effects*
Sulfonamides / pharmacokinetics*

Substances

Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Isoenzymes
Membrane Proteins
Pyrazoles
Sulfonamides
Cyclooxygenase 1
Cyclooxygenase 2
PTGS1 protein, human
PTGS2 protein, human
Prostaglandin-Endoperoxide Synthases
Celecoxib